ArticleJPGN reports2026
Responsible laboratory surveillance of pediatric patients with inflammatory bowel disease on biologic infusion therapy.
Article in JPGN reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The annual healthcare spending on pediatric inflammatory bowel disease (IBD) has increased over time. The objectives of the study were to investigate the cost of routine laboratory surveillance in pediatric IBD patients during outpatient maintenance biologic infusions and determine their impact on clinical management. We performed a retrospective chart review between June 30, 2020 and July 1, 2021 of subjects aged 0-21 years with IBD receiving maintenance biologic infusions at Stony Brook Children's Hospital (SBCH). Thirty-four subjects met the inclusion criteria. A total of 248 lab sets/infusions were reviewed during the study window. The average hospital charge for studies obtained per infusion was $1308.36 ± $136.66 with an average annual cost of $9543.44 ± $1885.44 per patient. Fifteen (6%) instances of change in clinical management were found. Our study suggests routine laboratory surveillance during infusions does not affect clinical management and may represent excess financial spending.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.